Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-Derived CD7 CAR T Cells in Relapsed or Refractory T-cell Leukemia/Lymphoma
NCT04689659Phase 2Completed
- Sponsor
- Beijing Boren Hospital
- Start
- Dec 2021
- Primary completion
- Apr 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of UTAA07 in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by Beijing Boren Hospital. Started Dec 2021; status: completed.
02
Drugs
UTAA07
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT04689659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689659.